DK0942754T3 - Konjugater anvendelige til behandlingen af prostatacancer - Google Patents
Konjugater anvendelige til behandlingen af prostatacancerInfo
- Publication number
- DK0942754T3 DK0942754T3 DK97946296T DK97946296T DK0942754T3 DK 0942754 T3 DK0942754 T3 DK 0942754T3 DK 97946296 T DK97946296 T DK 97946296T DK 97946296 T DK97946296 T DK 97946296T DK 0942754 T3 DK0942754 T3 DK 0942754T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- prostate cancer
- conjugates useful
- conjugates
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2922496P | 1996-10-30 | 1996-10-30 | |
| GBGB9626309.0A GB9626309D0 (en) | 1996-12-18 | 1996-12-18 | Conjugates useful in the treatment of prostate cancer |
| US4292197P | 1997-04-04 | 1997-04-04 | |
| GBGB9718160.6A GB9718160D0 (en) | 1997-08-28 | 1997-08-28 | Conjugates useful in the treatment of prostate cancer |
| PCT/US1997/019225 WO1998018493A2 (en) | 1996-10-30 | 1997-10-27 | Conjugates useful in the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0942754T3 true DK0942754T3 (da) | 2003-08-04 |
Family
ID=27451580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97946296T DK0942754T3 (da) | 1996-10-30 | 1997-10-27 | Konjugater anvendelige til behandlingen af prostatacancer |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0942754B1 (da) |
| JP (1) | JP2000509407A (da) |
| KR (1) | KR100508199B1 (da) |
| AR (1) | AR008907A1 (da) |
| AT (1) | ATE239509T1 (da) |
| AU (1) | AU726434B2 (da) |
| BG (1) | BG64768B1 (da) |
| BR (1) | BR9712589A (da) |
| CA (1) | CA2268738A1 (da) |
| CO (1) | CO4930281A1 (da) |
| CZ (1) | CZ155599A3 (da) |
| DE (1) | DE69721810T2 (da) |
| DK (1) | DK0942754T3 (da) |
| DZ (1) | DZ2333A1 (da) |
| EA (1) | EA002066B1 (da) |
| EE (1) | EE03858B1 (da) |
| ES (1) | ES2196374T3 (da) |
| HK (1) | HK1024876A1 (da) |
| HR (1) | HRP970566A2 (da) |
| HU (1) | HUP0000651A3 (da) |
| ID (1) | ID21358A (da) |
| IL (1) | IL129356A0 (da) |
| IS (1) | IS5025A (da) |
| NO (1) | NO992069L (da) |
| PE (1) | PE17399A1 (da) |
| PL (1) | PL333004A1 (da) |
| PT (1) | PT942754E (da) |
| SK (1) | SK57399A3 (da) |
| TR (1) | TR199901485T2 (da) |
| TW (1) | TW425286B (da) |
| WO (1) | WO1998018493A2 (da) |
| YU (1) | YU21399A (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9815116A (pt) * | 1997-12-02 | 2000-10-10 | Merck & Co Inc | Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna |
| CA2238257A1 (en) * | 1998-05-22 | 1999-11-22 | Universite De Montreal | Endocytosis of amf-r and uses thereof in cancer therapy |
| JP2002520369A (ja) * | 1998-07-17 | 2002-07-09 | アメリカ合衆国 | 水溶性薬剤およびその製造方法 |
| US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| JP2003518000A (ja) * | 1998-12-11 | 2003-06-03 | コールター ファーマシューティカル，インコーポレイティド | プロドラッグ化合物およびその調製方法 |
| US6552166B1 (en) | 1999-10-19 | 2003-04-22 | Merck & Co., Inc. | Process for the preparation of conjugates useful in the treatment of prostate cancer |
| GB9924759D0 (en) * | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
| CA2387901A1 (en) * | 1999-10-27 | 2001-05-03 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
| TR200202183T2 (tr) | 2000-03-15 | 2007-01-22 | Bristol-Myers Squibb Pharma Company | Peptidazla bölünebilen, hedeflenmiş antineoplastik ilaçlar ve terapetik kullanımları |
| WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2005035003A2 (en) * | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| CN100372862C (zh) * | 2003-11-05 | 2008-03-05 | 天津和美生物技术有限公司 | 具有抗癌活性的阿霉素衍生物及其制备方法和应用 |
| WO2008067495A2 (en) * | 2006-11-29 | 2008-06-05 | Rutgers, The State University Of New Jersey | Chemotherapeutic conjugates and methods of use |
| CN101225094A (zh) | 2007-01-18 | 2008-07-23 | 天津和美生物技术有限公司 | 具有抗癌活性的蒽醌四环类化合物 |
| AU2010223565B2 (en) * | 2009-03-09 | 2016-06-23 | Ktb Tumorforschungsgesellschaft Mbh | Prodrugs |
| EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| KR20240096553A (ko) | 2012-01-12 | 2024-06-26 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3253419A1 (en) | 2015-02-02 | 2017-12-13 | The University of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| EP3377103B2 (en) | 2015-11-19 | 2025-03-12 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN116635054A (zh) | 2020-12-22 | 2023-08-22 | 科比欧尔斯公司 | 包括四肽部分的化合物 |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
| WO1997014416A1 (en) * | 1995-10-18 | 1997-04-24 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
-
1997
- 1997-10-24 HR HR9718160.6A patent/HRP970566A2/hr not_active Application Discontinuation
- 1997-10-27 AU AU51497/98A patent/AU726434B2/en not_active Ceased
- 1997-10-27 WO PCT/US1997/019225 patent/WO1998018493A2/en not_active Application Discontinuation
- 1997-10-27 AT AT97946296T patent/ATE239509T1/de not_active IP Right Cessation
- 1997-10-27 EE EEP199900179A patent/EE03858B1/xx not_active IP Right Cessation
- 1997-10-27 KR KR10-1999-7003846A patent/KR100508199B1/ko not_active IP Right Cessation
- 1997-10-27 HU HU0000651A patent/HUP0000651A3/hu unknown
- 1997-10-27 BR BR9712589-0A patent/BR9712589A/pt not_active Application Discontinuation
- 1997-10-27 ES ES97946296T patent/ES2196374T3/es not_active Expired - Lifetime
- 1997-10-27 TR TR1999/01485T patent/TR199901485T2/xx unknown
- 1997-10-27 EA EA199900428A patent/EA002066B1/ru not_active IP Right Cessation
- 1997-10-27 PT PT97946296T patent/PT942754E/pt unknown
- 1997-10-27 EP EP97946296A patent/EP0942754B1/en not_active Expired - Lifetime
- 1997-10-27 DK DK97946296T patent/DK0942754T3/da active
- 1997-10-27 SK SK573-99A patent/SK57399A3/sk unknown
- 1997-10-27 DE DE69721810T patent/DE69721810T2/de not_active Expired - Fee Related
- 1997-10-27 CA CA002268738A patent/CA2268738A1/en not_active Abandoned
- 1997-10-27 IL IL12935697A patent/IL129356A0/xx not_active IP Right Cessation
- 1997-10-27 YU YU21399A patent/YU21399A/sh unknown
- 1997-10-27 PL PL97333004A patent/PL333004A1/xx unknown
- 1997-10-27 CZ CZ991555A patent/CZ155599A3/cs unknown
- 1997-10-27 ID IDW990259A patent/ID21358A/id unknown
- 1997-10-27 JP JP10520593A patent/JP2000509407A/ja not_active Ceased
- 1997-10-28 TW TW086115986A patent/TW425286B/zh not_active IP Right Cessation
- 1997-10-28 CO CO97063170A patent/CO4930281A1/es unknown
- 1997-10-29 AR ARP970105032A patent/AR008907A1/es not_active Application Discontinuation
- 1997-10-29 PE PE1997000970A patent/PE17399A1/es not_active Application Discontinuation
- 1997-10-29 DZ DZ970183A patent/DZ2333A1/xx active
-
1999
- 1999-04-13 IS IS5025A patent/IS5025A/is unknown
- 1999-04-29 NO NO992069A patent/NO992069L/no not_active Application Discontinuation
- 1999-05-26 BG BG103436A patent/BG64768B1/bg unknown
-
2000
- 2000-07-07 HK HK00104189A patent/HK1024876A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0942754T3 (da) | Konjugater anvendelige til behandlingen af prostatacancer | |
| NO994069L (no) | Forbindelser for immunoterapi av prostatacancer og fremgangsmate for anvendelse derav | |
| DK0972201T3 (da) | Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf | |
| DK0830864T3 (da) | Kombinationsbehandling til behandling af psykoser | |
| AU1958897A (en) | Egf-genistein conjugates for the treatment of cancer | |
| PT809996E (pt) | Conjugados de interferao | |
| NO974554L (no) | FremgangsmÕte for behandling av en underjordisk formasjon | |
| TR199800436A3 (tr) | Primidin türevlerinin kanserin önlenmesi için kullanilmasi. | |
| DE69936997D1 (de) | Paletteneinrichtung | |
| NO991647L (no) | Ledekile | |
| EP0926955A4 (en) | Conjugates useful in the treatment of prostate cancer | |
| DK0925069T3 (da) | Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer | |
| DK1176964T3 (da) | Brug af ET743 til behandling af cancer | |
| EP1104423A4 (en) | ANHYDRIDE-MODIFIED CANTHARIDINE ANALOGS SUITABLE FOR CANCER THERAPY | |
| DK0752870T3 (da) | Anvendelse af Mycobacterium til behandling af tumorer | |
| NO20022245L (no) | Onkolyttiske kombinasjoner for behandling av cancer | |
| IS5035A (is) | Aðferðir til varnar gegn brjóstakrabbameini | |
| DZ2665A1 (fr) | Conjugués utiles pour le traitement du cancer de la prostate. | |
| FI960658L (fi) | Uudet bis-naftalimidit syövän hoitamiseksi | |
| NO994631D0 (no) | Fremgangsmaater og sammensetninger for behandling av eggstokkreft | |
| DK1054868T3 (da) | Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi | |
| ZA9810974B (en) | Conjugates useful in the treatment of prostate cancer | |
| DK1140147T3 (da) | hCG-terapi til behandling af metastatisk brystcancer | |
| DK0964681T3 (da) | Antikonvulsive derivater til behandling af psoriasis | |
| KR970053540U (ko) | 침시술용 침관 |